| Similar Articles |
|---|
 |
Pharmaceutical Executive
October 1, 2010
William Looney |
Community: The Business of Life There is a practical lesson of reaching forward to tap the human community - and the moral connection - that will preserve the "license to operate" in the biopharmaceuticals business: the business of life.   |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive
November 1, 2012
Clark Herman |
Prix Galien: Night at the Museum Representatives of Big Pharma and trade association leaders at the New York Museum of Natural History had one purpose in mind: to recognize the latest innovations in new drugs and medical devices. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Russian Innovation: A Higher Mark For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products |
Pharmaceutical Executive
February 1, 2011
William Looney |
To Align an Audience, Find a Pulse All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too. |
Pharmaceutical Executive
December 1, 2012
William Looney |
The Puzzle Master: Dr. Guido Rasi Europe's chief regulator charts a strategy from many moving parts. |
Pharmaceutical Executive
September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Pharmaceutical Executive
July 1, 2013
William Looney |
Talent, Terror, and the Turnaround We offer news on 15 new Emerging Pharma Leaders, business innovation, and terrorism threats to the pharmaceutical industry. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive
January 21, 2014
William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Pharmaceutical Executive
November 1, 2011
Jeff Schindler |
Prix Galien USA 2011 Hollywood has its Academy Awards and the pharmaceutical industry celebrates its brightest research accomplishments at the Prix Galien USA. |
Pharmaceutical Executive
December 1, 2011
William Looney |
The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Mission to Transform Mid-career students at Brown University's new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos. |
Pharmaceutical Executive
September 1, 2011
Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Pharmaceutical Executive
January 21, 2014
William Looney |
For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist. |
Pharmaceutical Executive
November 1, 2013
William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Chemistry World
May 2007 |
Comment: A Matter of Ethics Scientists should embrace a universal ethical code. |
Pharmaceutical Executive
January 1, 2012
William Looney |
The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition. |
Pharmaceutical Executive
January 1, 2013
Clark Herman |
Who Lost Syria? Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey. |
Pharmaceutical Executive
July 1, 2011
William Looney |
Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them. |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
March 1, 2014
William Looney |
The Community Ethic Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. |
Pharmaceutical Executive
May 1, 2011
William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive
December 1, 2010
William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China. |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success. |
Pharmaceutical Executive
September 1, 2010
William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too. |
Pharmaceutical Executive
October 1, 2012
William Looney |
Three Ways to the Future Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. |
Pharmaceutical Executive
October 1, 2014
William Looney |
Youthquake You may not realize it, but the demographic "youth skew" in America is shaping healthcare and that's a good thing. |
Pharmaceutical Executive
June 1, 2012
Ben Comer |
Disruption in the C-Suite Clayton Christensen, author of "The Innovator's Dilemma," offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity. |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive
July 1, 2012
William Looney |
Less, But Better Pharm Exec's 2012 roster of Emerging Leaders is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace. |
Pharmaceutical Executive
April 1, 2011
Jeff Schindler |
Pharm Exec Wins a Neal Award! Pharm Exec's Editor-in-Chief William Looney was honored March 10 at American Business Media's Neal Awards for "Best Commentary" for his monthly editorial columns. |
Pharmaceutical Executive
August 1, 2013
William Looney |
One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future. |
Pharmaceutical Executive
May 1, 2014
William Looney |
What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk. |
Pharmaceutical Executive
June 1, 2005
Doretta Gasorek |
Who Sees the Halo? Insiders say pharma ethics reputations shine. Consumers don't see the glow. |
